Corresponding Author: Tom Shimabukuro, MD, MPH, MBA, Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30329 (tshimabukuro@cdc.gov).
Published Online: February 12, 2021. doi:10.1001/jama.2021.1967
Conflict of Interest Disclosures: None reported.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. Mention of a product or company name is for identification purposes only and does not constitute endorsement by the CDC.
Additional Contributions: We thank investigators from the CDC COVID-19 Response Team; the FDA Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research; and the Clinical Immunization Safety Assessment Project.
1.Oliver
SE , Gargano
JW , Marin
M ,
et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924. doi:
10.15585/mmwr.mm6950e2
PubMedGoogle ScholarCrossref 2.Oliver
SE , Gargano
JW , Marin
M ,
et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653-1656. doi:
10.15585/mmwr.mm695152e1PubMedGoogle ScholarCrossref 3.Shimabukuro
T , Nair
N . Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine.
JAMA. Published online January 21, 2021. doi:
10.1001/jama.2021.0600PubMedGoogle Scholar 4.CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020-January 10, 2021.
MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129. doi:
10.15585/mmwr.mm7004e1PubMedGoogle ScholarCrossref 7.Rüggeberg
JU , Gold
MS , Bayas
JM ,
et al; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Vaccine. 2007;25(31):5675-5684. doi:
10.1016/j.vaccine.2007.02.064
PubMedGoogle ScholarCrossref 8.Rossen
LM , Branum
AM , Ahmad
FB , Sutton
P , Anderson
RN . Excess deaths associated with COVID-19, by age and race and ethnicity—United States, January 26–October 3, 2020.
MMWR Morb Mortal Wkly Rep. 2020;69(42):1522-1527. doi:
10.15585/mmwr.mm6942e2
PubMedGoogle ScholarCrossref